ERBB4 and non-small cell lung carcinoma: Some of the ERBB4-mutants identified in NSCLC are ERBB4-activating because crucially situated at the dimerization interfaces of the extracellular (Y285C and D595V) and TK (D931Y and K935I) domains and possess oncogenic properties [170].